Abionic
ActiveOn the Switzerland Radar · not rankedDiagnostics · Switzerland
Develops a rapid nanofluidic diagnostic platform that measures blood biomarkers in minutes, including a sepsis-risk test cleared by the FDA in 2024, for hospitals.
Why Abionic is not ranked yet
How the Radar works →The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. Abionic enters the ranking once its public data is sufficient for the AI to estimate it. Next Switzerland edition: 11 Nov 2026.
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| Mar 2018 | Series C | USD 21M | — | Pierangelo Bottinelli |
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Switzerland · all sectors | Radar | — | Edition 0 · October 2026 | 11 Nov 2026 |
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Abionic as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in Switzerland
Full Switzerland ranking →Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.